TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23230311

Group type: EXPERIMENTAL
Intervention: Elevated soluble gp130 (fifth quintile versus all lower quintiles)
Number of subjects: 1452
Study: 21119517

Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with thoracic epidural block (group GT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: General anaesthesia (group GA)
Number of subjects: 66
Study: 19822979

Group type: EXPERIMENTAL
Intervention: Partial coverage (stent implantation for an occluded/culprit lesion only)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Full coverage (complete coverage of lesions)
Number of subjects: 76
Study: 17110824

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study: 15174325

Group type: EXPERIMENTAL
Intervention: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for unstable angina (UA)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for acute myocardial infarction (MI)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for hypertensive crises (HC)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional treatment alone for unstable angina (UA)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional treatment alone for acute myocardial infarction (MI)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Conventional treatment alone for hypertensive crises (HC)
Number of subjects: 338
Study: 11697832

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg/m2, days 1, 8 and 15
Number of subjects: 169

Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m2, day 1) plus Vindesine (3 mg/m2, days 1 and 15) (PV)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Cisplatin-vindesine (PV)
Number of subjects: 169
Study: 9399372

Group type: EXPERIMENTAL
Intervention: Scopolamine 200 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scopolamine 400 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scopolamine 600 micrograms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 30
Study: 7517825

Group type: EXPERIMENTAL
Intervention: Intramuscular tramadol 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intramuscular tramadol 300 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2897005

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre in the supine position
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Right carotid sinus massage
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Left carotid sinus massage
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diving reflex
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre while standing
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Physical manoeuvres overall
Number of subjects: 35
Study: 31901710

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU weekly for 8 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29175384

Group type: EXPERIMENTAL
Intervention: Prolonged targeted temperature management (TTM) for 48 hours
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard targeted temperature management (TTM) for 24 hours
Number of subjects: 115
Study: 28382551

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C + 235 mg vitamin E daily (AO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (CG)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (AO and CG)
Number of subjects: 33
Study: 25719419

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone associated with hyaluronic acid (group 3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone (group 2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cochlear implantation (control group 1)
Number of subjects: 18
Study: 23742777

Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anesthesia (IPLA) with bupivacaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham control with saline
Number of subjects: 41
Study: 20731310

Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction
Number of subjects: 67

Group type: COMPARATOR
Intervention: J-pouch reconstruction
Number of subjects: 67
Study: 18986534

Group type: EXPERIMENTAL
Intervention: 200 mg licofelone twice daily
Number of subjects: 355

Group type: COMPARATOR
Intervention: 500 mg naproxen twice daily
Number of subjects: 355
Study: 17034279

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Guideline standard therapy
Number of subjects: 1162
Study: 12514268

Group type: EXPERIMENTAL
Intervention: 15 g of psyllium per day for 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g of psyllium per day for 30 days (control)
Number of subjects: 0
Study: 10882617

Group type: EXPERIMENTAL
Intervention: PRO 542 (0.2-10 mg/kg)
Number of subjects: 0
Study: 8891083

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg for the first week, 40 mg for the remaining period)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 1799283

Group type: EXPERIMENTAL
Intervention: Fructose alone (50 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose alone (50 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fructose plus starch (50 g fructose + 15 g starch)
Number of subjects: 0
Study: 6306506

Group type: EXPERIMENTAL
Intervention: IV mannitol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IV furosemide
Number of subjects: 8
Study: 31250552

Group type: EXPERIMENTAL
Intervention: Incomplete ART adherence (reported by 109 participants, 7%)
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Exploratory analysis for SAA
Number of subjects: 1627

Group type: COMPARATOR
Intervention: Complete ART adherence (100%)
Number of subjects: 1627
Study: 29363988

Group type: EXPERIMENTAL
Intervention: 12-week brisk walking training (60-min of brisk walking, three times a week for a total of 12 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 12-week brisk walking training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 46
Study: 26928137

Group type: EXPERIMENTAL
Intervention: Gender-based motivational interviewing (GBMI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 35
Study: 25258143

Group type: EXPERIMENTAL
Intervention: Nuclear-Family cohort
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Twins cohort
Number of subjects: 914

Group type: COMPARATOR
Intervention: Environmental factors
Number of subjects: 914
Study: 23059357

Group type: EXPERIMENTAL
Intervention: Single 0.5 mL dose of virosomal subunit influenza vaccine (Inflexal V)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard two 0.25 mL doses given four weeks apart
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 205
Study: 20147716

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (10 mg/kg body weight, single infusion)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (1 mg/kg, 15 infusions every other day during a 29-day hospitalization)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 412

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 412
Study: 17980416

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide + 9 microg formoterol (twice daily, 100 microg per dose; n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide + 5 or 10 mg montelukast (once daily at bedtime; n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 5 or 10 mg montelukast (n = 20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (n = 20)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 100
Study: 16751933

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UH) (5,000 IU t.i.d.)
Number of subjects: 75
Study: 14521593

Group type: EXPERIMENTAL
Intervention: Ximelagatran 24 mg bid
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg bid
Number of subjects: 1838
Study: 10413638

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy including bedrest, anti-ischaemic medications, aspirin, and heparin.
Number of subjects: 733
Study: 8673551

Group type: EXPERIMENTAL
Intervention: Interest in participating in HIV preventive vaccine trials
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Perceived peer willingness to enroll in vaccine trials
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Optimism about success in vaccine development
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Recruitment setting (community settings vs. college campuses)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Vaccine‐induced seroconversion
Number of subjects: 630
Study: 1765571

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 or 0.50 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6136690

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 28884296

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (pamidronate and zoledronic acid, mean 2.95 infusions per patient)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 23
Study: 28913643

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 25636503

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (real) + Transcutaneous electrical nerve stimulation (real)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (sham) + Transcutaneous electrical nerve stimulation (sham)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (real) + Transcutaneous electrical nerve stimulation (sham)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (sham) + Transcutaneous electrical nerve stimulation (real)
Number of subjects: 92
Study: 23298790

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10Hz)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (1Hz)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study: 21178077

Group type: EXPERIMENTAL
Intervention: Cereal L fortified with electrolytic iron (54.5 mg iron/100 g cereal)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Cereal M fortified with ferrous fumarate (52.2 mg Fe/100 g)
Number of subjects: 95
Study: 18280335

Group type: EXPERIMENTAL
Intervention: MAL‐LPDL
Number of subjects: 15

Group type: COMPARATOR
Intervention: LPDL
Number of subjects: 15
Study: 16996833

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-dose TNK with abciximab and reduced-dose UFH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) with enoxaparin or abciximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard UFH
Number of subjects: 0
Study: 12679443

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dosage of 0.067 mg/kg.d until attainment of adult height
Number of subjects: 168

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 168
Study: 11782853

Group type: EXPERIMENTAL
Intervention: Metoprolol IR 50 mg 3 times daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Metoprolol CR/XL 100 mg once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 200 mg once daily
Number of subjects: 15
Study: 9386657

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Indomethacin and Ibuprofen (both treatments)
Number of subjects: 16
Study: 7904762

Group type: EXPERIMENTAL
Intervention: Fluphenazine (FPZ) 20 mg/day
Number of subjects: 156

Group type: COMPARATOR
Intervention: Fluphenazine (FPZ) 80 mg/day
Number of subjects: 156

Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Fluphenazine (FPZ) 20 mg/day (open phase)
Number of subjects: 156
Study: 3586115

Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (stress inoculation and control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heart rate monitoring
Number of subjects: 20
Study: 29148929

Group type: EXPERIMENTAL
Intervention: Alcohol-Wise (version 4.0, 3rd Millennium Classrooms) administered prior to first semester
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waitlist control (received Alcohol-Wise second semester)
Number of subjects: 76
Study: 27568507

Group type: EXPERIMENTAL
Intervention: MET + Family Check-Up (FCU)
Number of subjects: 97

Group type: COMPARATOR
Intervention: adolescent MET-only
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Older adolescents
Number of subjects: 97
Study: 25138685

Group type: EXPERIMENTAL
Intervention: Pain on Movement (POM) questionnaire
Number of subjects: 482

Group type: COMPARATOR
Intervention: Pain at rest on VAS
Number of subjects: 482

Group type: COMPARATOR
Intervention: Neck Disability Index (NDI)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Short-form 36 health survey questionnaire (SF-36)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Range of motion
Number of subjects: 482
Study: 23867222

Group type: EXPERIMENTAL
Intervention: Pocket PATH (Personal Assistant for Tracking Health)
Number of subjects: 0
Study: 21346067

Group type: COMPARATOR
Intervention: Placebo (group A, n = 32)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: MRrhTSH 0.01 mg (group B, n = 30)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: MRrhTSH 0.03 mg (group C, n = 33)
Number of subjects: 95
Study: 18678569

Group type: EXPERIMENTAL
Intervention: Cyclic electrical stimulation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EMG-triggered electrical stimulation
Number of subjects: 22
Study: 16339498

Group type: EXPERIMENTAL
Intervention: CLA isomeric mixture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 40
Study: 14636819

Group type: EXPERIMENTAL
Intervention: morphine 18 mg/70 kg intramuscular
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: morphine 10 mg/70 kg intravenous
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: hydromorphone 2 mg/70 kg intravenous
Number of subjects: 4

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4
Study: 11002953

Group type: EXPERIMENTAL
Intervention: 500 microg misoprostol given orally
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard oxytocic regimens (oxytocin, oxytocin with ergometrine, or ergometrine)
Number of subjects: 1000
Study: 8840306

Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/day oral calcitriol (calcitriol group, n = 8)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3 g/day calcium carbonate (CaCO3 group, n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Neither (control uraemic group, n = 8)
Number of subjects: 26
Study: 1729619

Group type: EXPERIMENTAL
Intervention: Topical 0.1 percent tretinoin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 58
Study: 3885699

Group type: EXPERIMENTAL
Intervention: Tiapamil (1.5 mg/kg intravenous bolus followed by 50 micrograms/kg/min infusion for 3 hours)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tiapamil
Number of subjects: 11
Study: 29973280

Group type: EXPERIMENTAL
Intervention: IAU+P4P
Number of subjects: 1173

Group type: COMPARATOR
Intervention: IAU
Number of subjects: 1173
Study: 27175664

Group type: EXPERIMENTAL
Intervention: Opioid group (fentanyl via IV PCA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ON-Q group (continuous wound infiltration of 0.5% ropivacaine with ON-Q pump and tramadol via IV PCA)
Number of subjects: 60
Study: 27366404

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (haemodynamic parameters)
Number of subjects: 82
Study: 22541165

Group type: EXPERIMENTAL
Intervention: 0-back test for 30 min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2-back test for 30 min
Number of subjects: 12
Study: 20018492

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin (16g/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent bolus dosing of piperacillin (4g every 6h)
Number of subjects: 16
Study: 18569677

Group type: EXPERIMENTAL
Intervention: Age 2 group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age 10 group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False event recall
Number of subjects: 0
Study: 16622039

Group type: EXPERIMENTAL
Intervention: 0.6 mg/h GTN for 1 week (n=17)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 100 nM, 300 nM, or 1 microM GTN during ex vivo expansion (n=10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment (n=11)
Number of subjects: 28

Group type: COMPARATOR
Intervention: EPCs expanded without GTN (n=10)
Number of subjects: 28
Study: 12533579

Group type: EXPERIMENTAL
Intervention: Fragment-Fissure herniations (89 patients)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Fragment-Contained herniations (42 patients)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Fragment-Defect herniations (33 patients)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: No Fragment-Contained herniations (16 patients)
Number of subjects: 187
Study: 11011494

Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 8970420

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 119
Study: 1461145

Group type: EXPERIMENTAL
Intervention: high-MUFA/low-CHO diet
Number of subjects: 10

Group type: COMPARATOR
Intervention: low-MUFA/high-CHO diet
Number of subjects: 10
Study: 6539224

Group type: EXPERIMENTAL
Intervention: 60 mg codeine phosphate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 60 mg dextromethorphan hydrobromide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30 mg codeine phosphate
Number of subjects: 8

Group type: COMPARATOR
Intervention: 30 mg dextromethorphan hydrobromide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 28930881

Group type: EXPERIMENTAL
Intervention: Total Motion Release (TMR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dynamic warm-up (TWG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dynamic warm-up after TMR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TMR after dynamic warm-up
Number of subjects: 20
Study: 30694205

Group type: EXPERIMENTAL
Intervention: eHealth intervention (ikherstel)
Number of subjects: 151
Study: 29061224

Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 (DPP-4) activity
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 (GLP-1) total activity
Number of subjects: 125
Study: 25214068

Group type: EXPERIMENTAL
Intervention: Pushable coil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Detachable coil
Number of subjects: 50
Study: 23475835

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contact lens (CL) treatment
Number of subjects: 0
Study: 21519726

Group type: EXPERIMENTAL
Intervention: Personalized weight loss diet (30% energy restriction) with macronutrient distribution of 40/30/30, high meal frequency (7/day), low glycemic index/load, high antioxidant capacity, and adherence to the Mediterranean diet.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group diet with the same energy restriction based on the American Heart Association pattern.
Number of subjects: 100
Study: 18972725

Group type: EXPERIMENTAL
Intervention: Three-combination needling method (acupuncture, acupoint-injection, fire-needle therapy)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Acupuncture and acupoint-injection (control group)
Number of subjects: 86
Study: 16939373

Group type: EXPERIMENTAL
Intervention: Microtapered needle (TN3305, 'Needle T')
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard thin wall needle (Micro‐Fine +, 31 gauge, 5 mm, 'Needle B')
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Comparison of both needles
Number of subjects: 99

Group type: COMPARATOR
Intervention: Both needles
Number of subjects: 99
Study: 12642637

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 16608

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 10713746

Group type: EXPERIMENTAL
Intervention: Borage oil supplementation (230 or 460 mg gamma‐linolenic acid per day for one week)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atopic mothers (no supplementation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non‐atopic mothers (control)
Number of subjects: 40
Study: 8884934

Group type: EXPERIMENTAL
Intervention: Alcohol (0.91 MJ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, 0.72 MJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water
Number of subjects: 20